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Abstract: 
Pulmonary delivery of therapeutic peptides and proteins has many advantages including 
high  relative  bioavailability,  rapid  systemic  absorption  and  onset  of  action  and  a  
non-invasive  mode  of  administration  which  improves  patient  compliance. In this study, 
we investigated the effect of spray drying (SD) and spray freeze-drying (SFD) on the 
stability and aerosol performance of Parathyroid hormone (PTH1-34) microparticles 
prepared for inhalation. Trehalose (a non reducing sugar) and Brij 97 (a non ionic 
surfactant) were evaluated as protein stabilizers against process induced degradation. 
Protein stability was assessed using circular dichroism (CD), fluorescence spectroscopy, 
modulated differential scanning calorimetry (MDSC), and in-vitro bioactivity. Aerosol 
performance of the formulations was assessed using the Andersen Cascade Impactor 
(ACI). SD-PTH formulations produced superior aerosol performance than their SFD 
counterparts. CD, fluorescence spectroscopy and bioactivity studies showed that PTH 
integrity was best conserved with the SD-PTH formulations than with the SFD 
formulations. Trehalose was most effective as a stabiliser with the bioactivity of SD-PTH 
containing trehalose being equivalent to that of unprocessed PTH.  
 
Keywords: Pulmonary delivery; parathyroid hormone; spray drying; spray-freeze drying; 
stability 
 
1. Introduction 
Bone disorders such as osteoporosis are a common occurrence in the aging population. 
An estimated 150 million people are known to suffer from osteoporosis worldwide and it 
has been reported to be more widespread in countries with large elderly populations (1). In 
1995, Barret-Connor predicted that the number of hip fractures in the USA will exceed 650 
000 and are likely to cost US$ 240 billion within 50 years due to population growth and 
increases in life expectancy(2). Parathyroid hormone (PTH), used either alone or in 
combination with other existing therapies have been recommended as the ideal treatment 
for osteoporosis (1). PTH is presently being marketed as Forteo by Eli Lilly for 
administration via the subcutaneous (SC) route(3). Although, clinical trials have shown that 
injected PTH (1-34) increases both bone mineral density (BMD) and bone mineral content 
(BMC) in comparison to placebo, concerns still exist regarding its safety (3). Adverse 
effects such as angina pectoris, asthenia, constipation, depression, dizziness, headache, 
hypercalcemia and hypertension have also been reported with the injected PTH (1-34) (3). 
A transient increase in serum calcium concentration occurs when 20 µg is administered to 
the patient beginning approximately 2 hours after administration (Forteo Product Insert, 
2002).A risk of osteosarcoma, a rare but serious malignant primary bone tumour has been 
reported (Forteo Product Insert, 2002, (4)). This incidence has been reported to be dose 
dependent(3-4). The reported adverse effects experienced with the parenteral 
administration of PTH and the inconvenience of chronic parenteral administration to the 
patient suggest that there is a need for the exploitation of alternative routes of 
administration. 
The large absorptive surface area, the very thin diffusion path to the bloodstream, the 
avoidance of first pass-hepatic metabolism, the elevated blood flow and the relatively low 
metabolic activity are some of the advantages involved in the delivery of peptides through 
the lung (5). Since many  proteins  do not  have  adequate  long-term  storage  stability  in  
a  solution form, dry powder formulations are preferred during formulation development. 
This is because molecular mobility  of  a  protein  is  greatly  reduced  in  the  solid  state  
resulting  in  improved biochemical stability (6). Dry powders are also favored from a 
bioavailablility standpoint. Studies conducted in our laboratory (results not shown) and 
elsewhere show that when compared to a solution formulation, the rate and extent of 
protein absorption across the pulmonary epithelium is higher with a dry powder 
formulation(7). Two studies have previously used PTH in a dry powder formulation for 
inhalation. One by Mannkind pharmaceuticals used the Technosphere technology that 
involved adsorbing PTH onto proprietary, diketopiperazine based excipients(8). Using this 
formulation, a relative bioavailability of 48% was reported in a clinical trial with 10 healthy 
human volunteers. The other study by Codrons et al. used spray drying to produce 
inhalable dry powder formulations of PTH containing a lipid, dipalmitoyl phosphatidyl 
choline (DPPC) as the main excipient(9). This study reported an absolute PTH 
bioavailability of 34% after intra-tracheal administration of the formulation in rats.  
The delivery of proteins and peptides through the lungs presents unique challenges 
including efficient delivery of expensive biomolecules to the lower lungs, avoiding rapid 
clearance and degradation in the lungs and finally facilitating peptide transport across the 
airway epithelium. For optimal absorption of peptide particles via the lungs, an 
aerodynamic diameter of 1-5µm is needed to reduce the loss of the drug either through 
inertial impaction in the oro-pharyngeal region of the airways or during expiration (10). 
Particle engineering can be used to prepare these inhalable particles. However, peptides 
are vulnerable to some of the stresses involved in these particle engineering processes 
due to the lability of their higher order structures (11-12). Excipients, e.g. sugars and non-
ionic surfactants are normally used to protect proteins during particle engineering(13-14). 
The main focus of studies done so far on inhaled PTH1-34 has been on the bioavailability of  
the  molecule  in  the  lungs  but  no  studies  to  date  have  assessed  the  effect  of  the 
formulation manufacturing process on the conformational stability and biological activity of  
PTH(8-9). In this study, we investigated the effect of spray drying and spray freeze-drying 
on the stability and aerosol performance of PTH (1-34) microparticles prepared for 
inhalation. Adsorption of proteins at the air-liquid interface or exposure to high 
temperatures can have an adverse impact on protein stability. Non-reducing sugars such 
as trehalose and sucrose are normally used to stabilise proteins against denaturation by 
acting as replacements for water molecules by forming hydrogen bonds with the protein 
molecule. This prevents/reduces protein unfolding and preserves its conformational 
stability(15). Furthermore, non-ionic surfactants such as Brijs and polysorbates help to 
exclude proteins from the air-liquid interface created during spray drying and spray freeze 
drying and so help to stabilise proteins during these processes(16). 
In this study, the stabilisation effect of trehalose (a non reducing sugar) and Brij 97 (a non 
ionic surfactant) on engineered peptide particles was assessed using analytical techniques 
such as circular dichroism, fluorescence spectroscopy, modulated differential scanning 
calorimetry (MDSC), and in-vitro bioactivity assay. Physical characterisation was also 
performed using SEM, tap density measurement and laser light diffraction. The aerosol 
performance of the formulations was assessed using the Andersen Cascade Impactor. 
 
2. Materials and Methods 
2.1. Materials 
Recombinant human parathyroid hormone (rhPTH 1-34) acetate (4117.8 Da) was supplied 
by Polypeptide Laboratories, California, USA. α-trehalose dihydrate (>99.5%) was 
supplied by Fluka Biochemika, USA. Brij 97 (Polyethylene glycol monooleyl ether), 
acetonitrile CHROMASOLV®, HPLC grade, sodium chloride (>99%) were all supplied by 
Sigma-Aldrich, Chemie GmbH, Buchs, Switzerland. Trifluoroacetic acid, Laboratory 
reagent grade was supplied by Fischer Scientific, Loughborough, UK. 
 
2.2. Methods 
2.2.1 Particle manufacture 
2.2.1.1 Spray drying 
5 mg/ml PTH solutions were prepared by dissolving the appropriate amount of the peptide 
powder in water. Where appropriate, 25 mg/ml α-trehalose dihydrate and/or 0.29 mg/ml 
Brij 97 were added as stabilisers. The concentration of the Brij 97 used is its critical micelle 
concentration (CMC) in water. Control formulations containing only 25 mg/ml of α-
trehalose dihydrate were also prepared (see Table 1 for the various formulations spray 
dried). All the formulations were corrected to pH 7 using 0.1M NaOH solution. Spray drying 
was performed using the B290 mini spray dryer (Bϋchi, Switzerland). The atomising air 
flow-rate was set 600 Nl/hr while the feed rate was 5 ml/min. The aspirator was at 90% 
and the inlet temperature was 97˚C. These parameters led to an outlet temperature of 
47±2˚C. A nozzle size of 0.7mm was used. The powder yields ranged between 26-76%. 
 
2.2.1.2 Spray freeze-drying 
For the spray freeze-drying process, solutions containing 5 mg/ml PTH and 25 mg/ml of α-
trehalose dihydrate was atomised using a 0.7mm co-axial nozzle (Bϋchi, Switzerland) into 
a container filled with liquid nitrogen at a feed rate of 5 ml/min. The atomising air flow-rate 
was set at 600 Nl/hr. The slurry formed was left for approximately 5 minutes on a bench to 
allow the nitrogen to evaporate before loading into a freeze dryer (Labconco Freezone 6, 
Missouri). The primary drying process was performed at -55˚C and lasted for 30 hours at 
0.40 mbar before the secondary drying processed was initiated at approximately 25˚C. 
This lasted for 18 hrs at 0.13 mbar. The powder yield was approximately 98%. 
 
2.2.2 Physical characterisation 
2.2.2.1 Scanning electron microscopy 
The morphologies of the manufactured and unprocessed peptide particles were observed 
under Tescan Mira XMU Variable Pressure Field Emission Scanning Electron Microscope 
(VPFESEM) (Tescan USA Inc. USA). Powders were mounted onto aluminium stubs using 
double sided adhesive tape and were then made electrically conductive by coating in a 
vacuum with a thin layer of gold. The coated specimen was then examined under the 
microscope operated at an acceleration voltage of 5kV.  
 
2.2.2.2 Particle size analysis 
The size distribution of manufactured powders was determined by laser light scattering 
with a Malvern MasterSizer Sirocco 2000 (Malvern Instrument Ltd., Worcestershire, UK). 
Approximately 25 mg of each powder was weighed into the sample holder. This was then 
dispersed using an air pressure of 3 bars, feed rate of 100% and an obscuration limit of 
<10%. Measurements were performed in triplicate.  
 
2.2.2.3 Tap density measurements 
The powder density (ρ) was determined by tap density according to the method used by 
Codrons et al. (2004). Briefly, specific amounts of the powder were weighed into a 5 ml 
measuring cylinder. The cylinder was then tapped 1000 times to allow the density to 
plateau. The final volume was recorded and the tapped density determined as the ratio of 
the weight and the volume in g/ml. Measurements were performed in triplicate. 
 
2.2.3 Circular dichroism (CD) 
CD measurements were performed with Aviv CD Spectrophotometer 410 (Aviv 
Biomedical, Inc. New Jersey) using 80 µg/ml of reconstituted solution of PTH in water. CD 
spectra were obtained in the far UV region (260-190 nm) using a quartz cell of 0.1 cm path 
length in order to probe the stability of the secondary structures of the engineered 
microparticles of PTH. A resolution of 0.1nm and a scanning speed of 6 nm/min with a 2-
second response time were applied. The CD signals were converted to molar ellipticity 
after an accumulation of five scans for each sample. 
2.2.4 Intrinsic Fluorescence spectroscopy 
Intrinsic fluorescence spectra were obtained using Perkin-Elmer LB55 Luminescence 
Spectrometer. Intrinsic fluorescence was monitored between 300 and 420 nm, with an 
excitation wavelength of 280 nm. The excitation and emission slits were set to 10 mm. 1 
µg/ml solution of PTH was used to generate an accumulation of five scans for each 
sample. 
 
2.2.5 In-vitro bioactivity assay for PTH 
Stimulation of cyclic AMP (cAMP) synthesis was used to determine the in vitro bioactivity 
of PTH (1-34) (17). MC3T3-E1 (subclone 4) cells were grown in minimum essential 
medium alpha medium (GIBCO) with 10% fetal bovine serum and 100 units/ml penicillin 
and streptomycin. The cells were passaged every 4–5 days. They were plated at 
50,000cells/cm2 in 12-well plates and induced to differentiate with the addition of ascorbic 
acid (50µg/ml) and β-glycerophosphate (10mM). The cells were used for the bioactivity 
assay after 5-7 days, when maximal PTH-1 receptor expression is reported to be occur 
(18). The confluent cells in each well were treated for 5 min with 500µl of 0.5 mM of 
phosphodiesterase inhibitor, isobutylmethylxanthine (IBMX) (Sigma) in KRB. To perform 
the assay, 5 different samples from each formulation were weighed out and dissolved in 
Kreb’s Ringer Buffer (KRB) to achieve a PTH1-34 concentration of 100ng/ml. Following 
treatment with IBMX, the cells were washed with KRB and subsequently treated with PTH 
containing samples as prepared above. Samples equivalent to 45ng of PTH were added to 
each well. After incubating for 20min at 37ºC, cells were lysed using a lysis buffer (Catalog 
No. 250006, Cell Biolabs, Inc., CA, USA) and incubated at 4ºC for 20 minutes. The cells 
were then scraped off the surface using a cell scraper. The cell suspension was then 
transferred to a centrifuge tube and stored at -20ºC until analyzed for cAMP. cAMP was 
measured using an enzyme immunoassay (EIA) kit (Biomedical Technologies Inc., 
Stoughton, MA) following the manufacturer’s instructions. The frozen samples in the 
centrifuge tubes were thawed and centrifuged at 10000rpm for 10 minutes. The 
supernatants were used for cAMP estimation.  
 
2.2.6 Differential scanning calorimetry 
Solid state thermal stability of PTH (1-34) particles was determined by Differential 
scanning calorimetry (MDSC) using a Q100 MDSC (TA Instrument, Leatherhead, UK). 
Approximately 10 mg of PTH (1-34) powder was weighed into an aluminium pan, which 
was hermetically sealed. An empty hermetically sealed pan was loaded into the reference 
compartment while sample-containing pan was placed in the sample compartment. 
Equilibration was performed at -60 ºC. Sample was heated at a rate of 2 ºC/min between -
60 and 250 ºC. 
 
2.2.7 Andersen Cascade Impactor Testing (ACI) 
The in-vitro deposition patterns of the peptide formulations were assessed using the eight-
stage ACI. The ACI set-up was calibrated at 28.3 l/min. For each formulation, powder 
containing an equivalent of 1 mg of peptide was weighed into HPMC capsules before 
loading the capsules into a spinhaler® dry powder device. The content of the capsule was 
then dosed into the ACI before collection of the plates on each stage and washing with 
deionized water. The content of peptide on each plate was quantified by UV absorption at 
280 nm.  
 
3. Results and Discussion 
3.1 Morphology of peptide microparticles 
Figures 1 shows the morphologies of unprocessed and engineered PTH microparticles. 
The spray dried PTH:trehalose particles appear corrugated unlike the spray freeze dried 
peptide particles which appear porous. In Figure 1A, the unprocessed PTH particles 
appear plate-like without any definite shape. However, following the spray drying process, 
the spray dried neat PTH (Figure 1C) appear spherical with corrugated surfaces. Particles 
with such a corrugated morphology have been reported to display a superior flow property 
in comparison to particles with smooth surfaces (18). This is due to the fact that particles 
with corrugated surfaces have less interparticulate contact area which leads to reduced 
Van der Waal forces. The improved flowability of the corrugated particles ultimately leads 
to improved aerosol properties. The addition of trehalose to the peptide formulations at the 
ratio of 1:5 (peptide:trehalose) did not produce any discernible changes in the morphology 
of the microparticles (Figures 1B and 1C) as compared to the corresponding neat 
peptides. 
An interesting observation was made when Brij 97 was added to the PTH:trehalose 
formulation (1:5:0.058, PTH:trehalose:Brij 97) (Fig. 1D). While the morphology of the 
microparticles produced did not change, the particles appear more cohesive, forming 
agglomerates when compared to the Brij-free spray dried PTH:trehalose microparticles. 
The presence of agglomerates may be attributed to the surface enrichment of the particles 
by the surfactant. The solute concentration of the formulations seemed to have an effect 
on the morphology and particle size of the spray freeze dried peptide particles. The 
formulations containing trehalose (PTH:trehalose 1:5) produced spherical but porous 
particles as seen in Figures 1F.  
 
3.2 Particle size analysis and tapped density measurements 
Table II shows the particle size distribution of the PTH particles produced by both spray 
drying and spray freeze drying in comparison to the unprocessed PTH particles. While the 
unprocessed PTH particles had a geometric diameter of approximately 27 µm, the spray 
dried particles including the neeat PTH, PTH:trehalose and PTH:trehalose:Brij had particle 
sizes between 3 and 4 µm. This suggests that the concentration of the solute did not have 
any discernible effect on the particle size spray dried PTH particles since all other 
parameters were kept constant. However, the particle size of the spray freeze dried 
PTH:trehalose composite was approximately 13µm. Particles manufactured by spray 
freeze drying have been reported to have bigger particle sizes in comparison to spray 
dried particles(19-20) . Nevertheless, the porous nature of such particles makes them 
ideal for inhalation because they tend to have lower densities as seen in Table II, when 
compared to their spray dried counterparts. Furthermore, their relatively bigger size helps 
to avoid engulfment by alveoli macrophages(10, 21) . 
 
3.3 Circular dichroism (CD) 
CD is a widely used technique in the determination of both the secondary and the tertiary 
structures of proteins/peptides(22-23) . Information concerning the secondary structures of 
proteins is normally obtained in the far UV region (190-260 nm) while the near UV region 
(250-320 nm) gives information about the tertiary structure. The far UV region of the CD 
spectrum has been explored in this study in-order to determine the effect of stabiliser 
(trehalose and Brij 97) on the secondary structure of PTH following particle engineering. 
Reports from previous CD studies  revealed that PTH (1-34) has an α-helical secondary 
structure(22-23). The result obtained from unprocessed PTH (1-34) is consistent with the 
published CD data for PTH (1-34) in the far UV spectrum. Figure 2 revealed that the 
unprocessed PTH (1-34) had an α-helical secondary structure. However, following spray 
drying, the neat PTH spectra showed some perturbation in the secondary structure. The 
downward loop around 200 to 210 nm was not as intense as in the unprocessed PTH 
which suggests a conversion to β-sheet(22) . The same occurrence was observed in the 
CD spectra for the PTH:trehalose:Brij 97 composite. However, when trehalose alone was 
used as a stabiliser in the spray dried and spray freeze-dried PTH composites, the 
secondary structure was restored without any sign of perturbation (Figure 2). 
 
3.4 Intrinsic fluorescent intensity 
The stability of the tertiary structure of spray dried and spray freeze-dried PTH (1-34) was 
determined using intrinsic fluorescence spectroscopy(24) . Fluorescence measurement is 
a high-throughput method used in protein formulation and characterisation studies(25) . 
Proteins that contain the hydrophobic amino acids tryptophan, tyrosine or phenylalanine 
are used in intrinsic fluorescence assays. Fluorescence intensity provides information on 
the local conformation and environment of these fluorophores. Being hydrophobic, 
tryptophan, tyrosine and phenylalanine produce a highly intensive fluorescence emission 
between 300-400nm when the protein is in a folded state(25) . However, fluorescence 
quenching occurs when unfolding (denaturation) occurs due to the hydrophobic amino 
acids being exposed to water (hydrophilic). A decrease in fluorescence intensity is 
normally observed when perturbations occur in the secondary structure of proteins. Figure 
3a shows the fluorescence spectra of the different spray dried PTH formulations studied in 
comparison to the unprocessed PTH. The spectra of these PTH formulations produced a 
similar lambda max (approximately 358 nm). However, while the unprocessed PTH and 
the spray dried PTH:trehalose formulations had maximum fluorescence intensities of 498 
and 539 units respectively, the spray dried neat PTH and PTH:trehalose:Brij formulations 
had intensities of 156 and 157 units respectively. Figure 3b represents the fluorescence 
spectrum of the spray freeze dried PTH:trehalose formulation in comparison to the 
corresponding spray dried formulation and the unprocessed PTH. The maximum intensity 
of the spray freeze dried PTH:trehalose formulation was 257 units in comparison  to the 
539 observed for its spray dried counterpart. 
 
3.5 In-vitro bioactivity assay of PTH 
The invitro activity of the engineered PTH particles was determined using a previously 
published method(17) . This is based on the invitro stimulation of cyclic AMP (cAMP) 
synthesis. The results are presented in Figure 4. The in vitro bioactivity data show a 
correlation with the fluorescence and CD results. The spray dried neat PTH and spray 
dried PTH:trehalose:Brij 97 formulations produced the lowest but similar bioactivity, 
stimulating the synthesis of approximately 0.016 and 0.024 pmol cAMP/ng of PTH 
respectively. However, the spray dried PTH:trehalose formulation produced a bioactivity 
comparable to that of the unprocessed PTH, 0.162 pmol cAMP/ng of PTH for the former 
and 0.217 pmol cAMP/ng of PTH for the latter. T-test statistical analysis showed that there 
was no significant difference (p<0.05) in the bioactivity of the two formulations. The spray 
freeze dried PTH:trehalose produced an inferior bioactivity (0.099 pmol cAMP/ng of PTH) 
in comparison to its spray dried counterpart. 
The spray freeze drying process has been reported to subject proteins to different stresses 
such as the air-liquid interface and the freeze concentration induced aggregation(11, 26) . 
This could explain why the bioactivity of the spray freeze dried PTH:trehalose formulation 
was lower than that of the corresponding spray dried formulation. Nevertheless, spray 
drying also subjects proteins to the air-liquid interface which has been reported to be the 
main stress mechanism responsible for the denaturation / aggregation of proteins during 
the process(10) . Data presented in Figures 4 above suggests that proteins possibly react 
to stresses in different ways and that the effects of different stresses on the stability of 
proteins cannot be generalised. 
  
3.7 Differential Scanning Calorimetry 
Figure 5 presents the MDSC thermal profiles of the different PTH composites. Calorimetry 
has been used in this study to help with better understanding of the mechanism through 
which trehalose stabilizes spray dried PTH and also to understand whether any sort of 
interaction occurred between the Brij 97 and trehalose in the presence of PTH. The 
thermal profile of the spray dried neat trehalose (Figure 5D) shows a glass transition (Tg) 
at approximately 50˚C. This transition was also observed in the spray dried PTH:trehalose 
and spray dried PTH:trehalose:Brij MDSC profiles suggesting that the presence of PTH 
does not affect the Tg of trehalose. Nevertheless, the recrystallisation of the spray dried 
trehalose to the α-polymorph was observed at approximately 145˚C and its subsequent 
melting at approximately 150˚C is represented by the endothermic peak (Figure 5D). The 
endothermic peak at approximately 201˚C represents the melting of the β-polymorph of 
trehalose (Figure 5D) [26]. The thermal profile of the composite containing PTH;trehalose 
(Figure 5F) shows the presence of the β-polymorph of trehalose only with only a “minor 
transition” around the α-polymorph. This suggests the interaction of the PTH with trehalose 
only allows for transition to the β-polymorph without any evidence of α-polymorph. An 
interesting profile was observed when Brij 97 was added to the PTH:trehalose composite 
(i.e PTH:trehalose:Brij). Only the α-polymorph of trehalose was observed without any β-
polymorphic transition (Figure 5E). This suggest that Brij 97 actually interacts with the 
trehalose in the presence of PTH and this probably explains why the combination of Brij 
and trehalose does not have the same stabilising effect as when only trehalose was used 
as the stabilising excipient. 
3.8  Aerosol performance test using ACI           
Tables III  shows the deposition patterns of PTH powder formulations as delivered by the 
spinhaler® DPI device. The FPF of spray-dried PTH formulation (55%) was not 
significantly different from that produced by the spray freeze-dried PTH formulation (49%). 
These FPFs correlate with the respective mass median aerodynamic diameters (MMAD). 
The MMAD of the spray dried PTH:trehalose formulation was 2.41µm in comparison to 
that of the spray freeze-dried formulation which was 2.71 µm. This is quite interesting as it 
is normally believe that large, porous particles always have superior aerodynamic 
properties in comparison to their solid particles counterpart (19, 21) . It has been 
previously reported  that the aerosol performance of dry powder formulations is not only 
depended on the particle size and particle porosity but also on the morphology of the 
particles(27-28). Particles with corrugated surfaces may produce superior aerosol 
performance than particles with smooth surfaces because of the improved flow brought 
about by the reduced inter-particulate van der Waal forces. Particles with corrugated 
surfaces normally have reduced interparticulate contact area which leads to reduced van 
der Waal forces (27-28) . This leads to improved flow properties especially in dry powder 
formulations without a carrier. Furthermore, the spray dried PTH: trehalose produced a 
higher FPF (55%) in comparison to the corresponding Brij 97 containing formulation which 
produced an FPF of 30% (Table 5). This is in agreement with the SEM data which showed 
that the Brij 97 containing particles were agglomerated and this possibly explains the FPF 
value. 
 
4.0 Conclusions 
The ACI and SEM data suggests that the morphology of particles in a DPI formulation has 
almost the same effect (if not greater) as the particle size and density of the particles. 
Spray-dried PTH formulations produced superior aerosol performance than their spray 
freeze-dried counterparts and this could be attributed to the roughness (corrugation) of the 
particles by spray drying. Furthermore, CD, fluorescence spectroscopy and bioactivity data 
suggest that trehalose when used alone as a stabilising excipient produced a superior 
stabilising effect than when used in combination with a non-ionic surfactant. DSC data 
suggest that an unfavourable interaction exists between the trehalose and Brij 97, which 
could be responsible for the detrimental effect observed when Brij was included in the 
formulation. 
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Figure Legends: 
Figure 1. Scanning electron micrographs (SEM) of PTH (1-34) microparticles. A. 
Unprocessed PTH, C. Spray dried neat PTH (reorder images) B. Spray dried 
PTH:trehalose 1: 5, D. Spray dried PTH:trehalose:Brij 97 1:5:0.058, E. Spray dried neat 
trehalose and F. Spray freeze-dried PTH:trehalose 1:5 
  
Figure 2. CD spectra (far UV region) of reconstituted PTH microparticles in double distilled 
de-ionised water. From top to bottom, spray dried PTH:trehalose:Brij 97; spray dried neat 
PTH; unprocessed PTH; spray freeze-dried PTH and spray dried PTH:trehalose 
 
Figure 3a. Fluorescence spectra comparing the tertiary structures of (from top to bottom) 
Spray dried PTH:trehalose; unprocessed PTH; spray dried neat PTH and spray dried 
PTH:trehalose:Brij 97 
 
Figure 3b. Fluorescence spectra comparing the tertiary structures of (from top to bottom) 
Spray dried PTH:trehalose; unprocessed PTH; spray freez-dried PTH:trehalose 
 
Figure 4: The in vitro stimulation of cAMP synthesis by the different PTH formulations 
(Mean± SD, n=5) 
 
Figure 5: MDSC thermal profiles of A. Spray freeze-dried PTH:trehalose; B. Spray dried 
neat PTH; C. Unprocessed PTH; D. Spray dried neat trehalose; E. Spray dried 
PTH:trehalose:Brij; F. Spray dried PTH:trehalose 
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Table I Formulations of PTH (1-34). 
Formulation PTH (mg/ml) Trehalose 
(mg/ml) 
Brij 95 (mg/ml) Ratio by 
weight 
1* 5 25 - 1:5 
2 5 - - - 
3 5 25 0.29 1:5:0.058 
4 - 25 - - 
*This formulation was both spray dried and spray freeze dried while the rest were only 
spray dried. 
 
 
Table II. Summary of the particle size distribution and tapped densities of PTH (n=3). 
 
Formulation Particle size  
(MMD#, µm)* 
Tapped density (g/ml)* 
Unprocessed PTH 27.3 ± 2.5 0.122 ± 0.001 
SD neat PTH 3.9 ± 0.2 0.203 ± 0.001 
SD PTH:tre 3.6 ± 0.1 0.165 ± 0.002 
SD PTH:tre: Brij 3.2 ± 0.1 0.190 ± 0.001 
SFD PTH:tre 12.6 ± 1.5 0.007± 0.001 
  * Mean±SD 
 # Mass Median Diameter 
 
Table III. Summary of deposition patterns for PTH using the  
Andersen Cascade Impactor (n=3, Mean±SD). 
Formulation FPFa (%) MMADb (µm) GSDc EDd (%) 
Unprocessed PTH  34±4 3.92±0.42 3.32±0.38 95±2 
SD neat PTH  84±10 1.95±0.85 2.72±0.24 84±9 
SD PTH:tre 55±15 2.41±0.75 3.17±0.52 55±15 
SFD PTH:trehalose  49±13 2.71±0.52 3.84±1.54 88±6 
SD PTH:tre:Brij 97 30±3 3.55±0.39 3.49±0.23 90±3 
a Fine Particle Fraction 
b Mass Median Aerodynamic Diameter 
c Geometric Standard Deviation 
d Emitted Dose 
 
 
 
